ANDAORALTABLET
Approved
Jun 2025
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
IBUPROFEN AND FAMOTIDINE (ibuprofen and famotidine) by Aurobindo Pharma is histamine h2 receptor antagonists [moa]. First approved in 2025.
Drug data last refreshed 1w ago
Mechanism of Action
Histamine H2 Receptor Antagonists
Pharmacologic Class:
Histamine-2 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Started Apr 2012
12 enrolled
Juvenile Idiopathic Arthritis
Company
Worked on IBUPROFEN AND FAMOTIDINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.